A malicious NPM package, ambar-src, mimicking a popular JavaScript framework, was downloaded nearly 50,000 times in a few ...
ImmunityBio has surged over 200% YTD, yet I see little fundamental justification for its current $10B enterprise value. Click here to read why IBRX is a Sell.
Palantir Technologies posted a Q4 Rule of 40 score of 127%, with revenue up 70% YoY. Click here to find out why I rate PLTR a Strong Buy.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果